These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 37776546

  • 41. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
    Klein S, Nolte I, Rumstedt K, Sehn M, Raue JF, Weiner F, Treese JS, Beyerbach M, Bach JP.
    BMC Vet Res; 2021 Sep 25; 17(1):310. PubMed ID: 34563187
    [Abstract] [Full Text] [Related]

  • 42. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.
    Yata M, McLachlan AJ, Foster DJ, Hanzlicek AS, Beijerink NJ.
    J Vet Cardiol; 2016 Dec 25; 18(4):310-325. PubMed ID: 27613648
    [Abstract] [Full Text] [Related]

  • 43. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q, Heaney A, Langenfeld-McCoy N, Boler BV, Laflamme DP.
    BMC Vet Res; 2019 Nov 27; 15(1):425. PubMed ID: 31775756
    [Abstract] [Full Text] [Related]

  • 44. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
    Troia R, Sabetti MC, Crosara S, Quintavalla C, Romito G, Mazzoldi C, Fidanzio F, Cescatti M, Bertazzolo W, Giunti M, Dondi F.
    J Vet Intern Med; 2022 Nov 27; 36(6):2053-2062. PubMed ID: 36196592
    [Abstract] [Full Text] [Related]

  • 45. Biopterin status in dogs with myxomatous mitral valve disease is associated with disease severity and cardiovascular risk factors.
    Reimann MJ, Häggström J, Mortensen A, Lykkesfeldt J, Møller JE, Falk T, Olsen LH.
    J Vet Intern Med; 2014 Nov 27; 28(5):1520-6. PubMed ID: 25274442
    [Abstract] [Full Text] [Related]

  • 46. Evaluation of the diagnostic value of the renal resistive index as a marker of the subclinical development of cardiorenal syndrome in MMVD dogs.
    Szczepankiewicz B, Pasławska U, Siwińska N, Plens K, Pasławski R.
    J Renin Angiotensin Aldosterone Syst; 2021 Nov 27; 22(1):1470320321995082. PubMed ID: 33730896
    [Abstract] [Full Text] [Related]

  • 47. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
    Hezzell MJ, Boswood A, López-Alvarez J, Lötter N, Elliott J.
    J Vet Cardiol; 2017 Aug 27; 19(4):325-338. PubMed ID: 28734620
    [Abstract] [Full Text] [Related]

  • 48. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K, Kawamoto S, Osuga T, Morita T, Sasaki N, Morishita K, Ohta H, Takiguchi M.
    J Vet Intern Med; 2017 Mar 27; 31(2):316-325. PubMed ID: 28145607
    [Abstract] [Full Text] [Related]

  • 49. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N, Nolte I, Wall L, Sehn M, Raue J, Pilgram A, Rumstedt K, Bach JP.
    BMC Vet Res; 2019 Jul 09; 15(1):237. PubMed ID: 31288807
    [Abstract] [Full Text] [Related]

  • 50. Utility of cardiac MRI to diagnose myocardial ischemia and fibrosis in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
    Clark WA, Winter RL, Aarnes TK, Green EM, Mikrut K, Ruz P, Addison D, Rhinehart JD, Schober KE, Friel HT.
    Am J Vet Res; 2022 Aug 02; 83(10):. PubMed ID: 35905145
    [Abstract] [Full Text] [Related]

  • 51. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
    Mizuno M, Yamano S, Chimura S, Hirakawa A, Takusagawa Y, Sawada T, Maetani S, Takahashi A, Mizuno T, Harada K, Shinoda A, Uchida S, Takeuchi J, Mizukoshi T, Endo M, Uechi M.
    J Vet Med Sci; 2017 Jan 20; 79(1):29-34. PubMed ID: 27644192
    [Abstract] [Full Text] [Related]

  • 52. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ, Häggström J, Møller JE, Lykkesfeldt J, Falk T, Olsen LH.
    J Vet Intern Med; 2017 Mar 20; 31(2):295-302. PubMed ID: 28132441
    [Abstract] [Full Text] [Related]

  • 53. Pharmacokinetics of pimobendan following oral administration to New Zealand White rabbits (Oryctolagus cuniculus).
    Ozawa SM, Guzman DS, Hawkins MG, Diao SM, Masri AE, Gunther-Harrington CT, Knych HK.
    Am J Vet Res; 2022 Jan 12; 83(4):356-363. PubMed ID: 35038306
    [Abstract] [Full Text] [Related]

  • 54. Validation of a focused echocardiographic training program in first opinion practice.
    Dickson D, Harris J, Chang CH, Patteson M, Hezzell MJ.
    J Vet Intern Med; 2022 Nov 12; 36(6):1913-1920. PubMed ID: 36221315
    [Abstract] [Full Text] [Related]

  • 55. Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease.
    Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA.
    J Am Heart Assoc; 2021 May 04; 10(9):e018923. PubMed ID: 33890477
    [Abstract] [Full Text] [Related]

  • 56. Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.
    Rešetar Maslov D, Farkaš V, Rubić I, Kuleš J, Beletić A, Beer Ljubić B, Šmit I, Mrljak V, Torti M.
    Int J Mol Sci; 2023 Apr 12; 24(8):. PubMed ID: 37108311
    [Abstract] [Full Text] [Related]

  • 57. Plasma and platelet serotonin concentrations in healthy dogs and dogs with myxomatous mitral valve disease.
    Mangklabruks T, Surachetpong SD.
    J Vet Cardiol; 2014 Sep 12; 16(3):155-62. PubMed ID: 25127665
    [Abstract] [Full Text] [Related]

  • 58. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Müller S, Menciotti G, Borgarelli M.
    J Vet Cardiol; 2017 Oct 12; 19(5):433-440. PubMed ID: 28964709
    [Abstract] [Full Text] [Related]

  • 59. Pharmacodynamics and Pharmacokinetics of Injectable Pimobendan and Its Metabolite, O-Desmethyl-Pimobendan, in Healthy Dogs.
    Pichayapaiboon P, Tantisuwat L, Boonpala P, Saengklub N, Boonyarattanasoonthorn T, Khemawoot P, Kijtawornrat A.
    Front Vet Sci; 2021 Oct 12; 8():656902. PubMed ID: 34490386
    [Abstract] [Full Text] [Related]

  • 60. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
    Valente C, Guglielmini C, Domenech O, Contiero B, Zini E, Poser H.
    PLoS One; 2020 Oct 12; 15(9):e0238440. PubMed ID: 32870923
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.